Benefits Of Oxygen Saturation Targeting Study (BOOST-II) dataset

This dataset includes 1135 participants receiving either a lower (85 to 89%) or a higher (91 to 95%) oxygen-saturation range in 15 centres in Australia. Baseline data will include demographics, antenatal glucocorticoid treatment, method of delivery and temperature at admission to the neonatal unit. Clinical outcomes will include survival or disability status, language or cognitive score (based on the Bayley III Developmental Assessment) as well as health status including cerebral palsy with GMFCS ≥2, severe visual loss and severe hearing loss (based on the Health Status Assessment or Short Health Status Questionnaire) at corrected age of 2 years.